Nahla Hasabou

2.3k total citations
30 papers, 467 citations indexed

About

Nahla Hasabou is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Nahla Hasabou has authored 30 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 13 papers in Genetics and 8 papers in Oncology. Recurrent topics in Nahla Hasabou's work include Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Nahla Hasabou is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Nahla Hasabou collaborates with scholars based in United States, Japan and France. Nahla Hasabou's co-authors include Neal D. Shore, Fong Wang, Laurence Klotz, Simon Chowdhury, Arnauld Villers, Steve van Os, Axel Heidenreich, D. Robert Siemens, Suman Bhattacharya and De Phung and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Nahla Hasabou

27 papers receiving 459 citations

Peers

Nahla Hasabou
Phillips Tl United States
Jonathan Somma United States
Brigitte Brux Germany
Evin Gulbahce United States
John Bernard France
Manali Bhave United States
Ruth Riisnaes United Kingdom
Alexis K. Smith United States
Ines Figueiredo United Kingdom
Dori Giroux United States
Phillips Tl United States
Nahla Hasabou
Citations per year, relative to Nahla Hasabou Nahla Hasabou (= 1×) peers Phillips Tl

Countries citing papers authored by Nahla Hasabou

Since Specialization
Citations

This map shows the geographic impact of Nahla Hasabou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nahla Hasabou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nahla Hasabou more than expected).

Fields of papers citing papers by Nahla Hasabou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nahla Hasabou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nahla Hasabou. The network helps show where Nahla Hasabou may publish in the future.

Co-authorship network of co-authors of Nahla Hasabou

This figure shows the co-authorship network connecting the top 25 collaborators of Nahla Hasabou. A scholar is included among the top collaborators of Nahla Hasabou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nahla Hasabou. Nahla Hasabou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Wang, Jianxiang, Bin Jiang, Li J, et al.. (2024). Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 38(11). 2410–2418. 2 indexed citations
4.
Perl, Alexander E., Mark J. Levis, Andrew H. Wei, et al.. (2024). Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2889–2889.
5.
Miyamoto, Toshihiro, Hee‐Je Kim, Yasushi Hiramatsu, et al.. (2024). A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia. International Journal of Hematology. 121(1). 56–67.
6.
Pratz, Keith W., Mohamad Cherry, Jessica K. Altman, et al.. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology. 41(26). 4236–4246. 27 indexed citations
7.
Perl, Alexander E., Naoko Hosono, Pau Montesinos, et al.. (2022). Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal. 12(5). 84–84. 27 indexed citations
8.
Pratz, Keith W., Mohamad Cherry, Nikolai A. Podoltsev, et al.. (2022). AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results. Clinical Lymphoma Myeloma & Leukemia. 22. S230–S230. 1 indexed citations
9.
Wang, Jianxiang, Bin Jiang, Li J, et al.. (2021). Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia. Blood. 138(Supplement 1). 695–695. 5 indexed citations
10.
Perl, Alexander E., Jessica K. Altman, Naoko Hosono, et al.. (2020). Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Blood. 136(Supplement 1). 22–23. 6 indexed citations
11.
Siemens, D. Robert, Laurence Klotz, Axel Heidenreich, et al.. (2017). Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. The Journal of Urology. 199(1). 147–154. 29 indexed citations
12.
Perl, Alexander E., Jörge E. Cortes, Stephen A. Strickland, et al.. (2017). An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.. Journal of Clinical Oncology. 35(15_suppl). TPS7067–TPS7067. 7 indexed citations
13.
Shore, Neal D., Simon Chowdhury, Arnauld Villers, et al.. (2016). Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet Oncology. 17(2). 153–163. 185 indexed citations
14.
Turzhitsky, Vladimir, Nahla Hasabou, Michael J. Goldberg, et al.. (2008). Investigating Population Risk Factors of Pancreatic Cancer by Evaluation of Optical Markers in the Duodenal Mucosa. Disease Markers. 25(6). 313–321. 19 indexed citations
15.
Roy, Hemant K., Andrew Gomes, Vladimir Turzhitsky, et al.. (2008). Spectroscopic Microvascular Blood Detection From the Endoscopically Normal Colonic Mucosa: Biomarker for Neoplasia Risk. Gastroenterology. 135(4). 1069–1078. 53 indexed citations
16.
Hensing, Thomas A., et al.. (2008). Identification of malignancy-associated change in buccal mucosa with partial wave spectroscopy (PWS): A potential biomarker for lung cancer risk. Journal of Clinical Oncology. 26(15_suppl). 11045–11045. 1 indexed citations
17.
Roy, Hemant K., Andrew Gomes, Vladimir Turzhitsky, et al.. (2008). Biophotonic Detection of Increased Microvascular Blood Content (EIBS) As a Marker of Field Carcinogenesis Detection: Potential Adjunctive Technology for Colonoscopy. Gastrointestinal Endoscopy. 67(5). AB131–AB131. 1 indexed citations
18.
Roy, Hemant K., Vladimir Turzhitsky, Young L. Kim, et al.. (2008). Spectral Slope from the Endoscopically-Normal Mucosa Predicts Concurrent Colonic Neoplasia: A Pilot Ex-Vivo Clinical Study. Diseases of the Colon & Rectum. 51(9). 1381–1386. 8 indexed citations
19.
Roy, Hemant K., Vladimir Turzhitsky, Andrew Gomes, et al.. (2008). 751 Prediction of Colonic Neoplasia Through Spectral Marker Analysis from the Endoscopically Normal Rectum: An Ex Vivo and In Vivo Study. Gastroenterology. 134(4). A–109. 3 indexed citations
20.
Garg, Jay, et al.. (2005). Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology. 25(4). 393–399. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Phillips Tl Breakdown of academic impact, for papers by Jonathan Somma Breakdown of academic impact, for papers by Brigitte Brux Breakdown of academic impact, for papers by Evin Gulbahce Breakdown of academic impact, for papers by John Bernard Breakdown of academic impact, for papers by Manali Bhave Breakdown of academic impact, for papers by Ruth Riisnaes Breakdown of academic impact, for papers by Alexis K. Smith Breakdown of academic impact, for papers by Ines Figueiredo Breakdown of academic impact, for papers by Dori Giroux
Rankless by CCL
2026